MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome
Table 1
Demographic and clinical data of the CG and patients with ACS.
CG median (IQR 25–75)
ACS median (IQR 25–75)
Reference value
Age (years)
53.5 ± 13
63 ± 11
—
Male/female
39/41
42/38
—
Glucose (mg/dL)
89 (76–102)
124 (102–226)
75–100
Cholesterol (mg/dL)
148 (123–168)
115 (97–154)
<200
Triglycerides (mg/dL)
86 (37–200)
88 (73–123)
<200
HDLc (mg/dL)
24 (13–33)
16 (13–23)
<60
LDLc (mg/dL)
55 (45–78)
39 (32–61)
<129
CK (IU/mL)
—
354 (109–690)
24–195
CK-MB (IU-mL)
—
36 (20–91)
<130
Troponine I (ng/mL)
—
0.9 (0.1–3.14)
0.1–0.4
hs-CPR (mg/L)
18 (3–36)
3 (1.6–3.9)
6.6–8.5
Risk factor
n (%)
n (%)
ACS diagnosis n (%)
Obesity
20 (25)
44 (55)
UA (32.5)
26
Diabetes mellitus type 2
4 (5)
40 (50)
STEMI (33.75)
27
Dyslipidemia
2 (1.6)
35 (43.75)
High blood pressure
16 (20)
49 (61.25)
NSTEMI (33.75)
27
Smoking
4 (5)
44 (55)
ACS: acute coronary syndrome; CG: control group; CK: creatine kinase; CK-MB: creatine kinase muscle and brain; HDLc: high density lipoprotein; IQR: interquartile range; LDLc: low density lipoprotein; NSTEMI: non-ST-segment elevation myocardial infarction; UA: unstable angina; and STEMI: ST-segment elevation myocardial infarction (STEMI). The upper limit of normal CK is defined by individual hospital laboratory standards.
